$ASTH
Astrana Health, Inc.

2013 Q3 Form 10-Q Financial Statement

#000114420413050838 Filed on September 16, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2012 Q3
Revenue $2.521M $1.649M
YoY Change 52.86% 50.81%
Cost Of Revenue $2.258M $1.206M
YoY Change 87.28% 28.35%
Gross Profit $226.7K $443.8K
YoY Change -48.93% 187.47%
Gross Profit Margin 8.99% 26.9%
Selling, General & Admin $1.600M $500.0K
YoY Change 220.0% 150.0%
% of Gross Profit 705.92% 112.67%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $6.528K $4.946K
YoY Change 31.99% 91.71%
% of Gross Profit 2.88% 1.11%
Operating Expenses $3.308M $506.8K
YoY Change 552.73% 113.2%
Operating Profit -$786.6K -$63.03K
YoY Change 1148.08% -24.37%
Interest Expense $200.6K $224.9K
YoY Change -10.82% 611.66%
% of Operating Profit
Other Income/Expense, Net -$194.1K -$3.139M
YoY Change -93.82% 7848.04%
Pretax Income -$980.7K -$3.202M
YoY Change -69.37% 2506.81%
Income Tax $0.00 $800.00
% Of Pretax Income
Net Earnings -$980.7K -$3.203M
YoY Change -69.38% 2507.46%
Net Earnings / Revenue -38.9% -194.18%
Basic Earnings Per Share -$0.03
Diluted Earnings Per Share -$0.03 -$1.032M
COMMON SHARES
Basic Shares Outstanding 36.35M shares 31.05M shares
Diluted Shares Outstanding 36.35M shares

Balance Sheet

Concept 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.300M $300.0K
YoY Change 333.33% 0.0%
Cash & Equivalents $1.075M $259.1K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00
YoY Change
Inventory
Prepaid Expenses $33.57K $42.37K
Receivables $1.426M $998.3K
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.752M $1.352M
YoY Change 103.55% 22.91%
LONG-TERM ASSETS
Property, Plant & Equipment $66.88K $44.19K
YoY Change 51.35%
Goodwill $33.20K $32.00K
YoY Change 3.75%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.98K $1.450K
YoY Change 2726.28%
Total Long-Term Assets $384.7K $115.6K
YoY Change 232.66% -80.73%
TOTAL ASSETS
Total Short-Term Assets $2.752M $1.352M
Total Long-Term Assets $384.7K $115.6K
Total Assets $3.137M $1.468M
YoY Change 113.72% -13.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $43.89K
YoY Change 811.43%
Accrued Expenses $600.0K $100.0K
YoY Change 500.0% -50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $300.0K
YoY Change -100.0%
Long-Term Debt Due $600.0K $900.0K
YoY Change -33.33%
Total Short-Term Liabilities $2.243M $4.471M
YoY Change -49.83% 645.2%
LONG-TERM LIABILITIES
Long-Term Debt $2.200M $200.0K
YoY Change 1000.0% -83.33%
Other Long-Term Liabilities $500.0K
YoY Change
Total Long-Term Liabilities $2.200M $700.0K
YoY Change 214.29% -41.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.243M $4.471M
Total Long-Term Liabilities $2.200M $700.0K
Total Liabilities $4.100M $5.076M
YoY Change -19.22% 141.7%
SHAREHOLDERS EQUITY
Retained Earnings -$13.40M -$5.478M
YoY Change 144.68%
Common Stock $31.05K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$999.3K -$3.746M
YoY Change
Total Liabilities & Shareholders Equity $3.137M $1.468M
YoY Change 113.72% -13.67%

Cashflow Statement

Concept 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$980.7K -$3.203M
YoY Change -69.38% 2507.46%
Depreciation, Depletion And Amortization $6.528K $4.946K
YoY Change 31.99% 91.71%
Cash From Operating Activities -$310.0K $70.00K
YoY Change -542.86% 16.67%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -310.0K 70.00K
Cash From Investing Activities -10.00K 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -320.0K 70.00K
YoY Change -557.14% 16.67%
FREE CASH FLOW
Cash From Operating Activities -$310.0K $70.00K
Capital Expenditures -$10.00K $0.00
Free Cash Flow -$300.0K $70.00K
YoY Change -528.57% 16.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-299469 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3239203 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2371828 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3355382 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1532117 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-3202826 USD
us-gaap Net Income Loss
NetIncomeLoss
-2381232 USD
dei Document Type
DocumentType
10-Q
CY2013Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1909714 USD
CY2013Q3 us-gaap Goodwill
Goodwill
33200 USD
dei Trading Symbol
TradingSymbol
AMEH
CY2013Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
40025 USD
CY2013Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
34614 USD
CY2013Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
243616 USD
CY2013Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
218640 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66877 USD
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68142 USD
dei Entity Registrant Name
EntityRegistrantName
Apollo Medical Holdings, Inc.
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-31
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34843441 shares
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34843441 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1252410 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1176727 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1426022 USD
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1582505 USD
CY2013Q1 us-gaap Due From Affiliate Current
DueFromAffiliateCurrent
5648 USD
CY2013Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33571 USD
CY2013Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
72628 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
2752028 USD
CY2013Q1 us-gaap Assets Current
AssetsCurrent
2872122 USD
CY2013Q1 us-gaap Goodwill
Goodwill
33200 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40981 USD
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30981 USD
CY2013Q3 us-gaap Assets
Assets
3136702 USD
CY2013Q1 us-gaap Assets
Assets
3223085 USD
CY2013Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
654034 USD
CY2013Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
159334 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2242992 USD
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1704750 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Period End Date
DocumentPeriodEndDate
2013-07-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35918441 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001083446
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35918441 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35918441 shares
CY2013Q3 us-gaap Senior Notes Current
SeniorNotesCurrent
594765 USD
CY2013Q1 us-gaap Senior Notes Current
SeniorNotesCurrent
594765 USD
CY2013Q3 us-gaap Minority Interest
MinorityInterest
-270153 USD
us-gaap Operating Expenses
OperatingExpenses
2885085 USD
us-gaap Operating Expenses
OperatingExpenses
863142 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1360387 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-924 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
455 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1170 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
450 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-171730 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3139000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
506804 USD
CY2013Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
994193 USD
CY2013Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
950651 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
385800 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
170000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
501858 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1532117 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3202026 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9404 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4800 USD
CY2013Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
394915 USD
CY2013Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
496052 USD
us-gaap Revenues
Revenues
5039612 USD
us-gaap Revenues
Revenues
3281295 USD
CY2013Q3 us-gaap Cost Of Services
CostOfServices
2366393 USD
CY2012Q3 us-gaap Cost Of Services
CostOfServices
1205673 USD
us-gaap Cost Of Services
CostOfServices
4226886 USD
us-gaap Cost Of Services
CostOfServices
2534332 USD
CY2013Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-391379 USD
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3223085 USD
CY2013Q3 us-gaap Revenues
Revenues
2593046 USD
CY2012Q3 us-gaap Revenues
Revenues
1649451 USD
CY2013Q1 us-gaap Liabilities
Liabilities
3614464 USD
CY2013Q1 us-gaap Minority Interest
MinorityInterest
-36503 USD
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3136702 USD
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
34844 USD
CY2013Q3 ameh Other Equity
OtherEquity
-401422 USD
CY2013Q1 ameh Other Equity
OtherEquity
-616014 USD
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12769699 USD
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11248566 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13403504 USD
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11022272 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
-999308 USD
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
-354876 USD
CY2013Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1269461 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
226653 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
443778 USD
us-gaap Gross Profit
GrossProfit
812726 USD
us-gaap Gross Profit
GrossProfit
746963 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1580654 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2872047 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
853405 USD
CY2013Q3 us-gaap Depreciation
Depreciation
6386 USD
CY2012Q3 us-gaap Depreciation
Depreciation
4946 USD
us-gaap Depreciation
Depreciation
13038 USD
us-gaap Depreciation
Depreciation
9737 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
1587040 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-63026 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2072359 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-116179 USD
CY2013Q3 ameh Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
0 USD
CY2012Q3 ameh Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
-2914549 USD
ameh Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
0 USD
ameh Change In Fair Value Of Warrant Liabilities
ChangeInFairValueOfWarrantLiabilities
-2790711 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
170806 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
224906 USD
us-gaap Interest Expense
InterestExpense
298299 USD
us-gaap Interest Expense
InterestExpense
448942 USD
CY2013Q3 us-gaap Due From Affiliate Current
DueFromAffiliateCurrent
0 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
95630 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
40895 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
70777 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
326916 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11773 USD
us-gaap Net Income Loss
NetIncomeLoss
-3360182 USD
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35801683 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31015904 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35327885 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30780543 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13038 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9737 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
637981 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
102556 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1030732 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
82508 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-156483 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4137 USD
us-gaap Increase Decrease In Due To Officers And Stockholders Current
IncreaseDecreaseInDueToOfficersAndStockholdersCurrent
0 USD
us-gaap Increase Decrease In Due To Officers And Stockholders Current
IncreaseDecreaseInDueToOfficersAndStockholdersCurrent
6342 USD
us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
-5648 USD
us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
3296 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-39057 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
14516 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1450 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43542 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-40688 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-298344 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64605 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11773 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10662 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10662 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
270000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
240000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
100000 USD
ameh Proceeds From Subscribed Common Stock
ProceedsFromSubscribedCommonStock
-430000 USD
ameh Proceeds From Subscribed Common Stock
ProceedsFromSubscribedCommonStock
0 USD
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
220000 USD
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
75683 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
94733 USD
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164361 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
259094 USD
us-gaap Interest Paid
InterestPaid
96663 USD
us-gaap Interest Paid
InterestPaid
15000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
9404 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
9040 USD
ameh Issuance Of Common Stock Value In Payment Of Financing Cost
IssuanceOfCommonStockValueInPaymentOfFinancingCost
101817 USD
ameh Issuance Of Common Stock Value In Payment Of Financing Cost
IssuanceOfCommonStockValueInPaymentOfFinancingCost
25661 USD
ameh Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
37320 USD
ameh Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
0 USD
ameh Shares Isuued For Prepaid Director Services
SharesIsuuedForPrepaidDirectorServices
0 USD
ameh Shares Isuued For Prepaid Director Services
SharesIsuuedForPrepaidDirectorServices
47520 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
2790711 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
3750000 shares
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
24200 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>1.</strong> &#160;&#160;&#160;&#160;&#160; <strong> Description of Business</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Apollo Medical Holdings, Inc. and its affiliated physician groups are a physician-centric, integrated healthcare delivery system serving Medicare, Commercial and Medi-Cal beneficiaries in California. As of July 31, 2013, ApolloMed&#8217;s physician network consisted of over 300 hospitalists, primary care physicians and specialist physicians primarily through our owned and affiliated physician groups. ApolloMed operates as a medical management holding company through the following wholly-owned subsidiary management companies: Apollo Medical Management, Inc. (&#8220;AMM&#8221;), Pulmonary Critical Care Management, Inc. (&#8220;PCCM&#8221;), Verdugo Medical Management, Inc. (&#8220;VMM&#8221;) and ApolloMed ACO, Inc. (&#8220;ApolloMed ACO&#8221;). Through AMM, PCCM, and VMM, the Company manages affiliated medical groups, which consists of ApolloMed Hospitalists (&#8220;AMH"), Los Angeles Lung Center (&#8220;LALC&#8221;), and Eli Hendel, M.D., Inc. (&#8220;Hendel&#8221;.) AMM, PCCM and VMM each operate as a physician practice management company (&#8220;PPM&#8221;) and are in the business of providing management services to physician practice corporations (&#8220;PPC&#8221;) under long-term management service agreements. ApolloMedACO participates in the Medicare Shared Savings Program (&#8220;MSSP&#8221;), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160; <strong>&#160;</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Consolidation of Maverick Medical Group, Inc. and ApolloMed Care Clinic</em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On February 1, 2013 AMM entered into a management services agreement with Maverick Medical Group, Inc. (&#8220;MMG&#8221;), a newly formed independent practice association (&#8220;IPA&#8221;). Prior to February 1, 2013 MMG had no business operations. Under the MMG management services agreement (&#8220;MSA&#8221;), AMM has exclusive authority and will perform all non-medical management and administrative services related to the ongoing business operations of MMG. In addition, AMM has agreed to provide working capital to MMG to fund its initial operations. The MSA has an initial term of 20 years and is not terminable by either party except in the case of gross negligence, fraud, or other illegal acts by Apollo, or bankruptcy of Apollo. AMM is the primary beneficiary of MMG under the MSA, and consolidated the financial statements of MMG from the date of execution of the management agreement.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>&#160;</em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On July 31, 2013 AMM entered into a management services agreement with ApolloMed Care Clinic (&#8220;ACC&#8221;), a newly formed physician practice&#160; corporation. Prior to July 31, 2013 ACC had no business operations. Under the ACC management services agreement (&#8220;ACC MSA&#8221;), AMM has exclusive authority and will perform all non-medical management and administrative services related to the ongoing business operations of MMG. In addition, AMM has agreed to provide working capital to ACC to fund its initial operations. The ACC MSA has an initial term of 20 years and is not terminable by either party except in the case of gross negligence, fraud, or other illegal acts by Apollo, or bankruptcy of Apollo. AMM is the primary beneficiary of ACC under the MSA, and consolidated the financial statements of ACC from the date of execution of the management agreement.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>&#160;&#160;</em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Going Concern</em></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company's financial statements are prepared using United States generally accepted accounting principles (&#8220;GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company incurred the following net operating loss and cash from operating activities for the six months ended July 31, 2013:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Net operating loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,072,359</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Cash used in operating activities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>298,344</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of July 31, 2013 the Company&#8217;s accumulated and stockholders&#8217; deficit was as follows:</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Accumulated deficit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>13,403,504</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Stockholders' deficit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,269,461</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> To date the Company has funded its operations from internally generated cash flow and external sources, including the proceeds from the issuance of debt and equity securities which have provided funds for near-term operations and growth. The current operating plan indicates that losses from operations may be incurred for all of fiscal 2014. Consequently, we may not have sufficient liquidity necessary to sustain operations for the next twelve months and this raises substantial doubt that we will be able to continue as a going concern. On January 31, 2013 the Company raised through a private placement offering $<font style=" FONT-SIZE: 10pt">880,000</font> of par value 9% Senior Subordinated Callable Convertible Promissory Notes maturing <font style=" FONT-SIZE: 10pt">February 15, 2016</font> (the &#8220;<font style=" FONT-SIZE: 10pt">9</font>% Notes&#8221;) and through July 31, 2013 had raised an aggregate of $<font style=" FONT-SIZE: 10pt">1.1</font> million in gross proceeds (see Note 5). In March, 2013, the Company initiated a private placement of up to <font style=" FONT-SIZE: 10pt">7,500,000</font> shares of its common stock at a price per share of $<font style=" FONT-SIZE: 10pt">0.40</font> (the &#8220;Equity Offering&#8221;), and has raised $<font style=" FONT-SIZE: 10pt">430,000</font> during the six months ended July 31, 2013 (see Note 6). The Company intends to use the net proceeds after issue costs from the 9% Notes and the Equity Offering for working capital and general corporate purposes.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> No assurances can be made that management will be successful in achieving its plan. If the Company is not able to raise substantial additional capital in a timely manner, the Company may be forced to cease operations.</div> </div>
CY2013Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1100000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><strong>Concentrations</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The Company had two major customers during the three months ended July 31, 2012 which contributed <font style=" FONT-SIZE: 10pt">15.8</font>% and <font style=" FONT-SIZE: 10pt"> 15.7</font>% of net revenues, respectively, and had three major customers during the three months ended July 31, 2012 which contributed <font style=" FONT-SIZE: 10pt">25.8</font>%, <font style=" FONT-SIZE: 10pt">11.0</font>% and <font style=" FONT-SIZE: 10pt">10.7</font>% of net revenues, respectively.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The Company had two major customers during the six months ended July 31, 2012 which contributed <font style=" FONT-SIZE: 10pt">16.8</font>% and <font style=" FONT-SIZE: 10pt"> 16.1</font>% of net revenues, respectively, and had three major customers during the six months ended July 31, 2012 which contributed <font style=" FONT-SIZE: 10pt">26.0</font>%, <font style=" FONT-SIZE: 10pt">10.7</font>% and <font style=" FONT-SIZE: 10pt">9.7</font>% of revenue, respectively.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The Company had two major customers that contributed <font style=" FONT-SIZE: 10pt">16.9</font>% and <font style=" FONT-SIZE: 10pt">9.5</font>% of accounts receivable, respectively, as of July 31, 2013.</div> </div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of Estimates</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</div> </div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Reclassifications</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Certain reclassifications have been made to the accompanying fiscal year 2013 consolidated financial statements to conform them to the fiscal year 2014 presentation.</div> </div>
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6567075 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
556286 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6230729 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
433670 shares
ameh Service Agreement Term
ServiceAgreementTerm
P20Y
CY2013Q3 ameh Number Of Customers
NumberOfCustomers
2 pure
CY2012Q3 ameh Number Of Customers
NumberOfCustomers
3 pure
ameh Number Of Customers
NumberOfCustomers
2 pure
ameh Number Of Customers
NumberOfCustomers
3 pure
us-gaap Share Based Compensation
ShareBasedCompensation
6350 USD
CY2013Q3 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
417171 USD
CY2013Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
500023 USD
CY2013Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
287 USD
CY2013Q1 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
1087 USD
CY2013Q3 us-gaap Interest Payable Current
InterestPayableCurrent
44338 USD
CY2013Q1 us-gaap Interest Payable Current
InterestPayableCurrent
9310 USD
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
36345 USD
CY2013Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
45316 USD
CY2013Q3 us-gaap Senior Notes
SeniorNotes
500000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
45000 USD
CY2013Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
50937 USD
CY2013Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
2163171 USD
CY2013Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1909714 USD
CY2013Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2013Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2013Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
100000 shares
CY2013Q2 ameh Aggregate Fair Value Of Stock Options
AggregateFairValueOfStockOptions
94162 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
9000000 shares
CY2013Q3 ameh Aggregate Fair Value Of Stock Options
AggregateFairValueOfStockOptions
678000 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1733000 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5300000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2815000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7115000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5255390 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.18
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.13
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.16
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.16
CY2013 ameh Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P9Y9M18D
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
P0Y
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
P0Y
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageRemainingContractualTerm
P0Y
ameh Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y6M
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue
0 USD
ameh Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedIntrinsicValue
0 USD
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue
0 USD
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodIntrinsicValue
0 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
3690000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
60000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
CY2013 ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning
P0Y
ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning
P0Y
CY2013Q1 ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue
36900 USD
ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodAggregateIntrinsicValue
600 USD
CY2013Q3 ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue
37500 USD
CY2013Q1 ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue
0.01
ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageFairValue
0.01
CY2013Q3 ameh Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue
0.01
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1045487 USD
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80930 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1668713 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
185064 USD
ameh Class Of Warrant Or Right Granted Intrinsic Value
ClassOfWarrantOrRightGrantedIntrinsicValue
0 USD
CY2013Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2936000 shares
ameh Share Based Compensation Arrangements By Share Based Payment Award Options Cancellation In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancellationInPeriodWeightedAverageExercisePrice
0.21
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Cancellation In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationInPeriodWeightedAverageRemainingContractualTerm
P9Y1M6D
ameh Number Of Warrants Granted
NumberOfWarrantsGranted
209000 shares
CY2013Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3145000 shares
ameh Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0 USD
ameh Class Of Warrant Or Right Cancelled
ClassOfWarrantOrRightCancelled
0 USD
ameh Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
ameh Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
0 shares
ameh Class Of Warrant Or Right Outstanding Intrinsic Value Beginning Balance
ClassOfWarrantOrRightOutstandingIntrinsicValueBeginningBalance
0 USD
CY2013Q3 ameh Class Of Warrant Or Right Outstanding Intrinsic Value Ending Balance
ClassOfWarrantOrRightOutstandingIntrinsicValueEndingBalance
0 USD
ameh Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3145000 shares
ameh Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P3Y6M14D
CY2013Q3 ameh Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3145000 shares
CY2013Q3 ameh Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights
0.2882
ameh Common Shares Issued And Outstanding
CommonSharesIssuedAndOutstanding
35918441 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2530000 shares
CY2013Q3 ameh Common Stock Issuable Upon Conversion Of Convertible Senior Notes
CommonStockIssuableUponConversionOfConvertibleSeniorNotes
62475082 shares
ameh Share Based Compensation Arrangement By Share Based Payment Award Options Cancellation In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationInPeriod
-1000000 shares

Files In Submission

Name View Source Status
0001144204-13-050838-index-headers.html Edgar Link pending
0001144204-13-050838-index.html Edgar Link pending
0001144204-13-050838.txt Edgar Link pending
0001144204-13-050838-xbrl.zip Edgar Link pending
ameh-20130731.xml Edgar Link completed
ameh-20130731.xsd Edgar Link pending
ameh-20130731_cal.xml Edgar Link unprocessable
ameh-20130731_def.xml Edgar Link unprocessable
ameh-20130731_lab.xml Edgar Link unprocessable
ameh-20130731_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R45.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R46.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
v354222_10q.htm Edgar Link pending
v354222_ex10-18.htm Edgar Link pending
v354222_ex10-19.htm Edgar Link pending
v354222_ex31-1.htm Edgar Link pending
v354222_ex31-2.htm Edgar Link pending
v354222_ex32-1.htm Edgar Link pending
v354222_ex32-2.htm Edgar Link pending